Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Joo Hyun | - |
dc.contributor.author | Park, Dong Ah | - |
dc.contributor.author | Ko, Min Jung | - |
dc.contributor.author | Yoo, Jeong-Ju | - |
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Ahn, Ji-Hyun | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Ahn, Sang Bong | - |
dc.date.accessioned | 2023-01-25T09:18:37Z | - |
dc.date.available | 2023-01-25T09:18:37Z | - |
dc.date.created | 2023-01-05 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 2075-4426 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/182180 | - |
dc.description.abstract | Hepatitis B (HBV) reactivation was observed to be more than 10% in patients receiving interferon-based therapy for hepatitis C (HCV) co-infection. At present, when direct-acting antiviral (DAA) has become the main treatment for HCV, there are few large-scale studies on the reactivation of HBV in these population. We studied HBV reactivation risk and prophylactic HBV treatment efficacy in HBV/HCV co-infected patients receiving DAA therapy. Relevant studies were selected from the Ovid-Medline, Ovid-EMBASE, Cochrane Central Register of Controlled Trials, KoreaMed, KMbase, and RISS databases through 4 September 2020. Data pooling was carried out using the random-effects method. We identified 39 articles with 119,484 patients with chronic (n = 1673) or resolved (n = 13,497) HBV infection under DAA therapy. When the studies were pooled, the HBV reactivation rate was 12% (95% confidence interval (CI) 6–19, I2 = 87%), indicating that this population needs careful attention. When stratified by baseline HBV DNA, the undetectable HBV DNA group showed a significantly lower risk of reactivation than the detectable HBV DNA group (odds ratio (OR) 0.30, 95% CI 0.11–0.86, I2 = 0%). Prophylactic HBV therapy reduced HBV reactivation risk (OR 0.25, 95% CI 0.07–0.92, I2 = 0%). Patients with a resolved HBV infection showed a negligible rate (0.4%) of HBV reactivation. In conclusion, patients with detectable HBV DNA levels warrant careful monitoring for HBV reactivation and may benefit from preventive anti-HBV treatment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.3390/jpm12121957 | - |
dc.identifier.scopusid | 2-s2.0-85144652042 | - |
dc.identifier.wosid | 000901164100001 | - |
dc.identifier.bibliographicCitation | Journal of Personalized Medicine, v.12, no.12, pp.1 - 12 | - |
dc.relation.isPartOf | Journal of Personalized Medicine | - |
dc.citation.title | Journal of Personalized Medicine | - |
dc.citation.volume | 12 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | VIRUS REACTIVATION | - |
dc.subject.keywordPlus | HBV REACTIVATION | - |
dc.subject.keywordPlus | LEDIPASVIR-SOFOSBUVIR | - |
dc.subject.keywordPlus | HCV INFECTION | - |
dc.subject.keywordPlus | NO EVIDENCE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | REPLICATION | - |
dc.subject.keywordPlus | COINFECTION | - |
dc.subject.keywordPlus | SUPPRESSION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordAuthor | direct–acting antivirals | - |
dc.subject.keywordAuthor | hepatitis B virus | - |
dc.subject.keywordAuthor | hepatitis C virus | - |
dc.subject.keywordAuthor | reactivation | - |
dc.identifier.url | https://www.mdpi.com/2075-4426/12/12/1957 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.